Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | HPGD | P15428 | 2/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.59 |
| ▸ | PDE10A | Q9Y233 | 4/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.49 |
| ▸ | NQO2 | P16083 | 2/20 | 0.44 |
| ▸ | ACACA | Q13085 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL951984 | 0.92 | LMNA (0.55) | LMNAHPGDSMN1; SMN2PDE10AKDM4E | |
| SCHEMBL31587740 | 0.91 | LMNA (0.56) | LMNAHPGDSMN1; SMN2PDE10AKDM4E | |
| Chimanine A SCHEMBL8588818 | 0.87 | HPGD (0.59) | LMNAHPGDSMN1; SMN2PDE10AKDM4E | |
| SCHEMBL14236725 | 0.85 | PDE10A (0.45) | LMNAHPGDSMN1; SMN2PDE10AKDM4E | |
| SCHEMBL8290938 | 0.83 | LMNA (0.58) | LMNAHPGDSMN1; SMN2PDE10AKDM4E | |
| SCHEMBL7068027 | 0.82 | ALOX15 (0.58) | LMNAHPGDSMN1; SMN2PDE10AKDM4E | |
| SCHEMBL3967007 | 0.82 | LMNA (0.57) | LMNAHPGDSMN1; SMN2PDE10AKDM4E | |
| SCHEMBL4658526 | 0.81 | MAPT (0.60) | LMNAHPGDSMN1; SMN2PDE10AKDM4E | |
| SCHEMBL4390702 | 0.79 | LMNA (0.54) | LMNAHPGDSMN1; SMN2PDE10AKDM4E | |
| SCHEMBL27701422 | 0.78 | ALOX15 (0.61) | LMNAHPGDSMN1; SMN2PDE10AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12247246-B2 | Identification of inhibitors of TcpC and TIR NADase activity | WASHINGTON UNIVERSITY (US) | 2025-03-11 | — | — | US | disclosed |
| US-20230272449-A1 | IDENTIFICATION OF INHIBITORS OF TCPC AND TIR NADase ACTIVITY | WASHINGTON UNIVERSITY | 2023-08-31 | — | — | US | disclosed |
| US-20200283820-A1 | IDENTIFICATION OF INHIBITORS OF TCPC AND TIR NADase ACTIVITY | WASHINGTON UNIVERSITY | 2020-09-10 | — | — | US | disclosed |
| WO-2011098829-A1 | NUCLEIC ACID COMPLEXES | PROCARTA BIOSYSTEMS LTD (GB) | 2011-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230272449-A1 | IDENTIFICATION OF INHIBITORS OF TCPC AND TIR NADase ACTIVITY | NADK, NAPRT, TIPARP | LMNA 3303/4885HPGD 563/4885SMN1; SMN2 4411/4885 |
| US-12247246-B2 | Identification of inhibitors of TcpC and TIR NADase activity | NADK, NAPRT, TIPARP | LMNA 3303/4885HPGD 563/4885SMN1; SMN2 4411/4885 |
| US-20200283820-A1 | IDENTIFICATION OF INHIBITORS OF TCPC AND TIR NADase ACTIVITY | NADK, NAPRT, TIPARP | LMNA 3303/4885HPGD 563/4885SMN1; SMN2 4411/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.